Vir Biotechnology, Inc. - Common Stock, $0.0001 par value (VIR) Institutional Ownership

13F Institutional Holders and Ownership History from Q4 2019 to Q4 2025

Type / Class: Equity / Common Stock, $0.0001 par value
Symbol: VIR on Nasdaq
Shares outstanding: 139,542,309
Price per share: $7.45
All holders as of 31 Dec 2025: Q4 2025
Total 13F shares: 115,516,195
Total reported value: $696,346,495
% of total 13F portfolios: 0%
Share change: -1,179,501
Value change: -$6,787,310
Number of holders: 213
Price from insider filings: $7.45

Reported Shares, Excluding Options vs Price

Reported Value, Excluding Options

Total Investors

Significant Owners of Vir Biotechnology, Inc. - Common Stock, $0.0001 par value (VIR) based on Schedule 13D/G filings

Filer	Ownership	Change %	Holdings Value	Net Change	Nb Shares	Change %	Reporting Name	Report Period
BlackRock, Inc.	11%		$93,255,785		14,826,039		BlackRock, Inc.	31 Mar 2025
SB INVESTMENT ADVISERS (UK) LTD	9.4%		$77,652,504		13,116,977		SB Investment Advisers (UK) Limited	31 Dec 2025

As of 31 Dec 2025, 213 institutional investors reported holding 115,516,195 shares of Vir Biotechnology, Inc. - Common Stock, $0.0001 par value (VIR). This represents 83% of the company’s total 139,542,309 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Vir Biotechnology, Inc. - Common Stock, $0.0001 par value (VIR) together control 69% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution	Ownership %	Shares Held	Share Change %	Portfolio %	Holdings Value
BlackRock, Inc.	12%	16,330,103	+2.3%	0%	$98,470,521
SB INVESTMENT ADVISERS (UK) LTD	9.4%	13,116,977	-21%	0.79%	$79,095,371
ARCH Venture Management, LLC	9.3%	12,916,663	0%	12%	$77,887,478
VANGUARD GROUP INC	9%	12,548,944	-2%	0%	$75,670,133
GSK plc	6.1%	8,550,954	0%	6.5%	$51,562,253
STATE STREET CORP	4.5%	6,229,555	+19%	0%	$37,564,217
FMR LLC	2.3%	3,158,416	-13%	0%	$19,045,246
MORGAN STANLEY	1.9%	2,679,145	-0.37%	0%	$16,155,254
DIMENSIONAL FUND ADVISORS LP	1.8%	2,536,277	-15%	0%	$15,292,107
ORBIMED ADVISORS LLC	1.7%	2,380,715	0%	0.31%	$14,355,711
GEODE CAPITAL MANAGEMENT, LLC	1.7%	2,328,207	+3.6%	0%	$14,041,408
GOLDMAN SACHS GROUP INC	1.1%	1,568,904	+3.1%	0%	$9,460,491
Aberdeen Group plc	1%	1,390,577	-8.9%	0.01%	$8,385,179
Balyasny Asset Management L.P.	0.98%	1,368,474		0.02%	$8,251,898
Hudson Bay Capital Management LP	0.95%	1,325,000	+45%	0.05%	$7,989,750
Candriam S.C.A.	0.74%	1,031,663		0.03%	$6,221,193
MILLENNIUM MANAGEMENT LLC	0.72%	1,002,606	-28%	0%	$6,045,714
BANK OF AMERICA CORP /DE/	0.67%	930,908	+132%	0%	$5,613,376
GordonMD Global Investments LP	0.67%	930,317	0%	4%	$5,609,812
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	0.65%	904,480	-21%	0%	$5,454,014
NORTHERN TRUST CORP	0.61%	848,469	-6.5%	0%	$5,116,269
AMERIPRISE FINANCIAL INC	0.52%	731,307	+276%	0%	$4,409,781
Boxer Capital Management, LLC	0.45%	625,000		0.82%	$3,768,750
RENAISSANCE TECHNOLOGIES LLC	0.44%	614,464	-47%	0.01%	$3,705,218
NORDEA INVESTMENT MANAGEMENT AB	0.44%	609,726	-15%	0%	$3,545,556

Institutional Holders of Vir Biotechnology, Inc. - Common Stock, $0.0001 par value (VIR) across Reporting Periods

Period	Reported Shares, Excl. Options	Value, Excl. Options	Value Change	Puts Notional Value	Calls Notional Value	Price (Median)	Investors
2025 Q4	115,516,195	$696,346,495	-$6,787,310	$328,032	$1,275,045	$6.03	213
2025 Q3	107,007,241	$610,804,612	-$19,864,453	$720,352	$1,356,125	$5.71	209
2025 Q2	110,838,661	$558,775,027	+$84,580,503	$757,512	$1,721,664	$5.04	211
2025 Q1	93,307,654	$604,780,740	+$27,869,791	$1,691,988	$1,666,008	$6.48	230
2024 Q4	88,707,515	$651,126,620	+$14,506,884	$1,720,915	$9,401,072	$7.34	202
2024 Q3	87,600,991	$656,230,226	-$4,592,687	$8,915,347	$947,485	$7.49	195
2024 Q2	88,056,992	$783,680,407	-$9,558,987	$1,170,350	$2,056,790	$8.90	213
2024 Q1	88,814,549	$899,654,431	+$7,160,790	$1,847,712	$1,788,958	$10.13	205
2023 Q4	88,171,139	$887,025,787	+$1,493,653	$1,536,162	$1,808,788	$10.06	202
2023 Q3	88,255,499	$826,977,393	-$227,669,705	$499,421	$855,481	$9.37	212
2023 Q2	90,761,353	$2,226,351,489	+$60,012,170	$19,758,915	$10,170,138	$24.53	222
2023 Q1	88,385,448	$2,056,730,043	+$54,021,550	$4,539,977	$6,822,764	$23.27	226
2022 Q4	86,118,572	$2,179,650,166	-$15,704,818	$1,867,878	$3,791,586	$25.31	219
2022 Q3	86,915,381	$1,675,900,472	-$11,606,508	$3,217,000	$3,344,000	$19.28	208
2022 Q2	86,086,454	$2,193,070,491	+$146,002,800	$4,526,000	$5,547,000	$25.47	201
2022 Q1	81,103,450	$2,086,374,530	-$14,155,763	$9,034,000	$13,586,000	$25.72	191
2021 Q4	78,095,522	$3,252,220,942	+$158,691,641	$34,880,000	$29,066,800	$41.87	203
2021 Q3	74,464,481	$3,240,626,324	-$19,547,865	$12,826,000	$21,398,000	$43.52	169
2021 Q2	74,156,851	$3,506,017,317	+$66,755,814	$11,422,000	$26,500,000	$47.28	156
2021 Q1	75,409,279	$3,865,770,922	-$99,056,866	$29,427,000	$28,792,000	$51.27	151
2020 Q4	76,141,156	$2,039,280,477	+$150,971,873	$12,794,000	$10,247,100	$26.78	136
2020 Q3	70,048,123	$2,405,706,821	+$553,884,772	$4,686,000	$4,785,000	$34.33	117
2020 Q2	53,528,634	$2,192,860,452	+$657,421,714	$9,431,000	$8,330,000	$40.97	109
2020 Q1	37,861,951	$1,297,525,769	-$4,041,452	$329,000	$370,000	$34.27	61
2019 Q4	36,584,366	$460,028,000	+$460,028,135			$12.57	38